Viridian Therapeutics: Promising FcRn Inhibitor Developments and Strong Buy Recommendation
Leerink Partners analyst Thomas Smith reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report) on November 12 and set a ...
What’s Happening With Amgen Stock?
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
Axsome Therapeutics: Strong Revenue Performance and Strategic Growth Initiatives Justify Buy Rating
Axsome Therapeutics (AXSM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami ...
BioSpace3d
After Decades of Failure, First Disease-Modifying Huntington’s Treatment on the Horizon
The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...